Using DNA methylation and AI imaging to detect lung cancer early

DNA Methylation Combined With Artificial Intelligence Imaging for Early Benign and Malignant Differentiation of Lung Nodules:an Observational,Single-center Clinical Trial(MAGIC Study)

This study is testing a new way to find lung cancer early by looking at DNA changes in blood and using advanced imaging technology to see if it helps catch the disease sooner.

Quick facts

• Study type: Observational
• Enrollment: 100 (estimated)
• Ages: 20 Years to 80 Years
• Sex: All
• Sponsor: The First Affiliated Hospital with Nanjing Medical University (other)
• Locations: 1 site (Nanjing, Jiangsu)
• Trial ID: NCT06220305 on ClinicalTrials.gov

What this trial studies

This study aims to improve the early diagnosis of lung cancer by combining DNA methylation analysis from peripheral blood with artificial intelligence imaging technology. It focuses on assessing the overall DNA methylation levels and specific gene alterations as potential tumor markers. By integrating these diagnostic methods, the study seeks to enhance the accuracy of lung cancer detection, ultimately aiming to reduce mortality rates associated with the disease.

Who should consider this trial

Good fit: Ideal candidates include patients with pulmonary nodules identified through imaging who are willing to undergo DNA methylation testing.

Not a fit: Patients who are pregnant, have a history of malignancy, or have undergone recent diagnostic procedures may not benefit from this study.

Why it matters

Potential benefit: If successful, this approach could lead to earlier and more accurate diagnoses of lung cancer, improving patient outcomes.

How similar studies have performed: While the combination of DNA methylation and AI imaging is a novel approach, similar studies have shown promise in enhancing cancer diagnostics.

Eligibility criteria

Inclusion Criteria:

* (1) Patients with pulmonary nodules diagnosed by imaging;
* (2) No contraindications to blood collection;
* (3) Voluntary completed DNA methylation testing;
* (4) Signed informed consent and performed all the study mandated procedures.

Exclusion Criteria:

* (1) Pregnant or lactating(6 months) women;
* (2) History of malignancy or known malignancy or precancerous lesions or known tuberculosis within 3 years;
* (3) Autoimmune system disorders;
* (4) Undergoing any diagnostic puncture therapy, such as percutaneous lung biopsy, transbronchial, pre-enrollment biopsy, or surgical procedures (within 6 months); (5) Recipients of organ transplants or prior non-autologous (allogeneic) bone marrow transplants or stem cell transplants; (6) Received antibiotic therapy within 14 days or applied a drug that elevates white blood cells within 45 days prior to the blood draw.

Where this trial is running

Nanjing, Jiangsu

• Jiangsu Province Hospital — Nanjing, Jiangsu, China (RECRUITING)

Study contacts

• Study coordinator: Linfu Zhou

Conditions: Lung Cancer Diagnosis